Biomarkers Improve Odds Of Approval, BIO Study Finds
BIO/Biomedtracker analysis strengthens the case for expanded use of drug development tools like biomarkers with finding that well-defined patient populations in clinical trials are associated with greater likelihood of approval.
You may also be interested in...
Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.
It now takes 13 drugs in Phase I to yield one marketed drug, compared to 19 in 2007 to 2011, according to new data from KMR Group.
FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.